Cue Biopharma, Inc.
CUE
$29.47
$0.210.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.94M | 2.15M | 2.95M | 421.00K | 1.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.94M | 2.15M | 2.95M | 421.00K | 1.58M |
| Cost of Revenue | 33.09M | 429.00K | 7.91M | 7.65M | 30.27M |
| Gross Profit | -11.15M | 1.72M | -4.96M | -7.23M | -28.69M |
| SG&A Expenses | 4.05M | 5.54M | 3.68M | 5.07M | 4.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.98M | 9.69M | 11.59M | 12.72M | 11.21M |
| Operating Income | 1.96M | -7.54M | -8.64M | -12.30M | -9.63M |
| Income Before Tax | 2.09M | -7.45M | -8.48M | -12.26M | -9.50M |
| Income Tax Expenses | 500.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.59M | -7.45M | -8.48M | -12.26M | -9.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.59M | -7.45M | -8.48M | -12.26M | -9.50M |
| EBIT | 1.96M | -7.54M | -8.64M | -12.30M | -9.63M |
| EBITDA | 2.64M | -7.46M | -8.54M | -12.20M | -9.53M |
| EPS Basic | 0.01 | -0.07 | -0.09 | -0.17 | -0.13 |
| Normalized Basic EPS | 0.01 | -0.05 | -0.06 | -0.10 | -0.08 |
| EPS Diluted | 0.01 | -0.07 | -0.09 | -0.17 | -0.13 |
| Normalized Diluted EPS | 0.01 | -0.05 | -0.06 | -0.10 | -0.08 |
| Average Basic Shares Outstanding | 107.99M | 100.87M | 95.46M | 74.25M | 74.24M |
| Average Diluted Shares Outstanding | 110.51M | 100.87M | 95.46M | 74.25M | 74.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |